198 related articles for article (PubMed ID: 23179483)
1. Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance) in children.
Schneider G; Schürholz H; Kirchin MA; Bücker A; Fries P
Pediatr Radiol; 2013 Jan; 43(2):202-11. PubMed ID: 23179483
[TBL] [Abstract][Full Text] [Related]
2. Safety and Diagnostic Efficacy of Gadobenate Dimeglumine in MRI of the Brain and Spine of Neonates and Infants.
Enterline DS; Martin KW; Parmar HA; Triulzi FM; Colosimo C
AJNR Am J Neuroradiol; 2019 Dec; 40(12):2001-2009. PubMed ID: 31727753
[TBL] [Abstract][Full Text] [Related]
3. Contrast-enhanced MRA of the renal and aorto-iliac-femoral arteries: comparison of gadobenate dimeglumine and gadofosveset trisodium.
Iezzi R; Soulez G; Thurnher S; Schneider G; Kirchin MA; Shen N; Pirovano G; Spinazzi A
Eur J Radiol; 2011 Feb; 77(2):358-68. PubMed ID: 19679417
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.
Bryant BJ; Im K; Broome DR
Clin Radiol; 2009 Jul; 64(7):706-13. PubMed ID: 19520215
[TBL] [Abstract][Full Text] [Related]
5. Quarter-dose (0.025 mmol/kg) gadobenate dimeglumine for abdominal MRI in patients at risk for nephrogenic systemic fibrosis: preliminary observations.
de Campos RO; Heredia V; Ramalho M; De Toni MS; Lugo-Somolinos A; Fuller ER; Semelka RC
AJR Am J Roentgenol; 2011 Mar; 196(3):545-52. PubMed ID: 21343495
[TBL] [Abstract][Full Text] [Related]
6. Incidence of immediate gadolinium contrast media reactions.
Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
[TBL] [Abstract][Full Text] [Related]
7. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
[TBL] [Abstract][Full Text] [Related]
8. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine.
Knopp MV; Bourne MW; Sardanelli F; Wasser MN; Bonomo L; Boetes C; Müller-Schimpfle M; Hall-Craggs MA; Hamm B; Orlacchio A; Bartolozzi C; Kessler M; Fischer U; Schneider G; Oudkerk M; Teh WL; Gehl HB; Salerio I; Pirovano G; La Noce A; Kirchin MA; Spinazzi A
AJR Am J Roentgenol; 2003 Sep; 181(3):663-76. PubMed ID: 12933457
[TBL] [Abstract][Full Text] [Related]
9. [Multicenter analysis of tolerance and clinical safety of the extracellular MR contrast agent gadobenate dimeglumine (MultiHance)].
Herborn CU; Jäger-Booth I; Lodemann KP; Spinazzi A; Goyen M
Rofo; 2009 Jul; 181(7):652-7. PubMed ID: 19291607
[TBL] [Abstract][Full Text] [Related]
10. A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (Gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology.
Runge VM; Armstrong MR; Barr RG; Berger BL; Czervionke LF; Gonzalez CF; Halford HH; Kanal E; Kuhn MJ; Levin JM; Low RN; Tanenbaum LN; Wang AM; Wong W; Yuh WT; Zoarski GH
Invest Radiol; 2001 Feb; 36(2):65-71. PubMed ID: 11224753
[TBL] [Abstract][Full Text] [Related]
11. Assessment of rates of acute adverse reactions to gadobenate dimeglumine: review of more than 130,000 administrations in 7.5 years.
Fakhran S; Alhilali L; Kale H; Kanal E
AJR Am J Roentgenol; 2015 Apr; 204(4):703-6. PubMed ID: 25794059
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of gadobenate dimeglumine in children 2 to 5 years of age undergoing MRI of the central nervous system.
Pirovano G; Kirchin MA; Lorusso V; Patel R; Shen N
J Magn Reson Imaging; 2015 Apr; 41(4):1096-103. PubMed ID: 24807269
[TBL] [Abstract][Full Text] [Related]
13. Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(®)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis?
Kirchin MA; Lorusso V; Pirovano G
Br J Radiol; 2015 Apr; 88(1048):20140526. PubMed ID: 25651409
[TBL] [Abstract][Full Text] [Related]
14. Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide.
Rowley HA; Scialfa G; Gao PY; Maldjian JA; Hassell D; Kuhn MJ; Wippold FJ; Gallucci M; Bowen BC; Schmalfuss IM; Ruscalleda J; Bastianello S; Colosimo C
AJNR Am J Neuroradiol; 2008 Oct; 29(9):1684-91. PubMed ID: 18599575
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Low-Dose Higher-Relaxivity and Standard-Dose Lower-Relaxivity Contrast Media for Delayed-Enhancement MRI: A Blinded Randomized Crossover Study.
Cheong BY; Duran C; Preventza OA; Muthupillai R
AJR Am J Roentgenol; 2015 Sep; 205(3):533-9. PubMed ID: 26295638
[TBL] [Abstract][Full Text] [Related]
16. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.
Knopp MV; Runge VM; Essig M; Hartman M; Jansen O; Kirchin MA; Moeller A; Seeberg AH; Lodemann KP
Radiology; 2004 Jan; 230(1):55-64. PubMed ID: 14695387
[TBL] [Abstract][Full Text] [Related]
17. Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain.
Runge VM; Parker JR; Donovan M
Invest Radiol; 2002 May; 37(5):269-80. PubMed ID: 11979153
[TBL] [Abstract][Full Text] [Related]
18. Signal quality of single dose gadobenate dimeglumine pulmonary MRA examinations exceeds quality of MRA performed with double dose gadopentetate dimeglumine.
Woodard PK; Chenevert TL; Sostman HD; Jablonski KA; Stein PD; Goodman LR; Londy FJ; Narra V; Hales CA; Hull RD; Tapson VF; Weg JG
Int J Cardiovasc Imaging; 2012 Feb; 28(2):295-301. PubMed ID: 21337023
[TBL] [Abstract][Full Text] [Related]
19. Detection of intracranial metastases: a multicenter, intrapatient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dosage.
Colosimo C; Ruscalleda J; Korves M; La Ferla R; Wool C; Pianezzola P; Kirchin MA
Invest Radiol; 2001 Feb; 36(2):72-81. PubMed ID: 11224754
[TBL] [Abstract][Full Text] [Related]
20. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function?
Nandwana SB; Moreno CC; Osipow MT; Sekhar A; Cox KL
Radiology; 2015 Sep; 276(3):741-7. PubMed ID: 25875973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
